Table 1. Characteristics of patients.
| Covariates | Global population (n=4,025) | Included patients (n=1,582) | ||
|---|---|---|---|---|
| Age (yr) | 67 (15) | 67 (14) | ||
| Tumor histology | ||||
| Clear cell and mucinous | 125 (3.10) | 50 (3.20) | ||
| Others | 3,900 (96.9) | 1,532 (96.8) | ||
| Tumor grade | ||||
| Grade I | 138 (3.4) | 52 (3.3) | ||
| Grade II | 303 (7.5) | 134 (8.5) | ||
| Grade III | 2,091 (52.0) | 826 (52.2) | ||
| Missing | 1,493 (37.1) | 570 (36.0) | ||
| FIGO tumor stage | ||||
| IIB | 29 (0.7) | 4 (0.3) | ||
| IIC | 16 (0.4) | 5 (0.3) | ||
| IIIA | 19 (0.5) | 3 (0.2) | ||
| IIIB | 100 (2.5) | 26 (1.6) | ||
| IIIC | 2,356 (58.5) | 891 (56.3) | ||
| IV | 1,505 (37.4) | 653 (41.3) | ||
| Cytoreductive surgery performed | ||||
| No | 955 (23.7) | 327 (21) | ||
| Yes | 3,070 (76.3) | 1,255 (79) | ||
| Post-operative lesions after IDS* | ||||
| Suboptimal (>1 cm residual) | 354 (11.5) | 157 (12.5) | ||
| Optimal (<1 cm residual) | 1,097 (35.7) | 475 (37.8) | ||
| Complete | 1,553 (50.6) | 598 (47.6) | ||
| Missing | 66 (2.1) | 25 (2.0) | ||
| Completeness of IDS† | ||||
| Incomplete IDS | 1,451 (47.3) | 632 (50.4) | ||
| Complete IDS | 1,553 (50.6) | 598 (47.6) | ||
| Missing | 66 (2.1) | 25 (2.0) | ||
| Tumor radiological response | ||||
| Complete or Partial response | 2,650 (65.8) | 1,141 (72.1) | ||
| Stable or progressive disease | 565 (14.0) | 235 (14.9) | ||
| Missing | 810 (20.1) | 206 (13.0) | ||
| Treatment type | ||||
| NACT followed by IDS | 2,864 (71.2) | 1,186 (75.0) | ||
| PDS followed by chemotherapy and second cytoreductive surgery | 207 (5.1) | 69 (4.4) | ||
| Chemotherapy only, and no surgery | 954 (23.7) | 327 (20.7) | ||
| Chemotherapy regimens | ||||
| Carboplatin + paclitaxel | 3,532 (87.8) | 1,381 (87.3) | ||
| Carboplatin monotherapy | 233 (5.8) | 95 (6.0) | ||
| Carboplatin + paclitaxel + other chemotherapy | 160 (4.0) | 86 (5.4) | ||
| Other regimens | 100 (2.5) | 20 (1.3) | ||
| Risk-disease groups† | ||||
| Low-risk disease | 1,094 (27.2) | 384 (24.3) | ||
| High-risk disease | 1,929 (47.9) | 852 (53.9) | ||
| Missing | 1,002 (24.9) | 346 (21.9) | ||
| BRCA1 mutation | ||||
| No | 1,078 (26.8) | 439 (27.7) | ||
| Yes | 191 (4.7) | 70 (4.4) | ||
| Missing/not tested | 2,756 (68.5) | 1,073 (67.8) | ||
| BRCA2 mutation | ||||
| No | 1,172 (29.1) | 472 (29.8) | ||
| Yes | 97 (2.4) | 37 (2.3) | ||
| Missing/not tested | 2,756 (68.5) | 1,073 (67.8) | ||
| BRCA1-2 mutation | ||||
| No | 981 (24.4) | 402 (25.4) | ||
| Yes | 288 (7.2) | 107 (6.8) | ||
| Missing/not tested | 2,756 (68.5) | 1,073 (67.8) | ||
Values are presented as median (interquartile range) or number of patients (%).
BRCA, BReast CAncer gene; FIGO, International Federation of Obstetrics and Gynecologists; IDS, interval debulking surgery; NACT, neoadjuvant chemotherapy; PDS, primary debulking surgery.
*From patients who received debulking surgery. †High-risk group: Stage IV and incompletely resected stage III diseases; BRCA1-2 mutation = at least one BRCA1 or BRCA2 mutation.